Key Proteo: Funding, Investors & Team (Aug 2026)
Key Proteo is a developer of a novel peptide screening for newborn babies. The company aims to improve and expand the current newborn screening programs and subsequently provide early intervention for genetic diseases before they are clinically manifested. It specializes in multiplex analysis for any extremely low-abundance proteins from a few drops of blood (DBS) using surrogate peptide markers by mass spectrometry. With this new technology, Key Proteo targets new or existing genetic conditions to change their clinical course and ensure a better quality of life for its patients.
Key Proteo has raised $3.0M across 1 funding round on record, the most recent an undisclosed round of $3.0M announced in May 2023.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Key Proteo Company Profile and Key Stats
Latest funding round on record: May 2023.
Key Proteo Funding Rounds
Key Proteo Founders and Leadership Team
Contact details for the Key Proteo team: 1 of 1 has an email address on file.
Start 14-day free trial →Key Proteo Funding Compared to Other Health Care Startups
Key Proteo's latest round of $3.0M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Key Proteo in Health Care and Seattle
Companies Similar to Key Proteo
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Key Proteo Funding FAQs
What does Key Proteo do?
Key Proteo is a developer of a novel peptide screening for newborn babies. The company aims to improve and expand the current newborn screening programs and subsequently provide early intervention for genetic diseases before they are clinically manifested. It specializes in multiplex analysis for any extremely low-abundance proteins from a few drops of blood (DBS) using surrogate peptide markers by mass spectrometry. With this new technology, Key Proteo targets new or existing genetic conditions to change their clinical course and ensure a better quality of life for its patients.
How much funding has Key Proteo raised?
Key Proteo has raised $3.0M across 1 round on record. The most recent is an undisclosed round of $3.0M announced in May 2023.
When did Key Proteo last raise funding?
Key Proteo's most recent funding round on record is an undisclosed round of $3.0M, announced in May 2023.
Who is the CEO of Key Proteo?
Steve Hahn is listed as CEO at Key Proteo.
Where is Key Proteo headquartered?
Key Proteo is based in Seattle, Washington, United States.
How many employees does Key Proteo have?
Key Proteo is in the 1-10 employee band.
How does Key Proteo's funding compare to other Health Care startups?
Key Proteo's latest round of $3.0M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Key Proteo Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Key Proteo is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.